Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus TAZIDIME.
CEFEPIME IN PLASTIC CONTAINER vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateWarfarin + Ceftazidime
"Warfarin may increase the anticoagulant activities of Ceftazidime."
Clinical Note
moderatePhenprocoumon + Ceftazidime
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."